DEA Eases Some Requirements for Clinical Trials on Cannabidiol

DEA Eases Some Requirements for Clinical Trials on Cannabidiol

WASHINGTON, DC — The Drug Enforcement Administration (DEA) says they are easing some of the requirements imposed by the Controlled Substances Act for researchers conducting clinical trials on cannabidiol (CBD), an extract of marijuana that has been used to reduce seizures in children, among other ailments.

According to a press release issued Wednesday by the DEA, the changes “will streamline the research process regarding CBD’s possible medicinal value and help foster ongoing scientific studies.”

Researchers who are conducting Food…

CONTINUE READING: Click Here to Continue Reading Article…